Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
China and EU regulators emphasize innovation, access, and collaboration as key policy aims in the pharmaceutical industry. The NIH proposes that drug patent licensees develop an 'access plan' with optional pricing commitments to promote access to products from taxpayer-funded inventions. Discussions are ongoing within the government on making treatments accessible.
“I am just totally focused on what get this treatment to people who need it,” @NIHDirector on ongoing discussions in gov’t about making treatments accessible and what NIH’s role is in that.
Odds this actually gets implemented? @PharmaPinkSheet #pinksheet #pharma: NIH Drug Patent Licensees Would Develop ‘Access Plan’ Under Proposal; Pricing Commitments Optional https://t.co/tFs1hBONGq
NIH Drug Patent Licensees Would Develop ‘Access Plan’ Under Proposal; Pricing Commitments Optional https://t.co/bcI1NIupmK #PinkSheet